ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2243

How Well Do The Three Generic Patient Reported Outcomes Measurement Information System Fatigue Instruments Perform In Rheumatoid Arthritis?

Susan J. Bartlett1,2, Ana-Maria Orbai3, Trisha Duncan3 and Clifton O. Bingham III3, 1Clinical Epidemiology, McGill University, Montreal, QC, Canada, 2Division of Rheumatology, Johns Hopkins University, Baltimore, MD, 3Rheumatology, Johns Hopkins University, Baltimore, MD

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Fatigue, measure, patient outcomes and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis-Clinical Aspects III: Outcome Measures, Socioeconomy, Screening, Biomarkers in Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: NIH Patient-Reported Outcomes Measurement Information System (PROMIS) has created highly precise and efficient instruments to measure patient-reported outcomes across health domains relevant to chronic medical conditions. PROMIS is available without charge, and many domains offer item banks for computer adaptive testing (CAT) through Assessment Center, a secure online management tool, in addition to paper-based short forms (SF) and single domain items that form the Global Health measure. PROMIS Fatigue item bank assesses both the experience of fatigue from mild tiredness to an overwhelming, debilitating, and sustained sense of exhaustion as well as impact on physical, mental and social activities. However, the feasibility, validity and psychometric performance of the three PROMIS measures has not been reported in persons with rheumatoid arthritis (RA) where fatigue is highly prevalent and disabling.

Methods: Data are from the baseline visit of the first 125 RA patients enrolled in an ongoing study integrating PROs into routine care at an academic RA clinic. Three PROMIS fatigue measures (CAT [average 5-8 items], 7-item SF and Global Health single item of fatigue) were administered in random order along with other legacy measures immediately before a routine clinic visit. Spearman correlations were used to evaluate convergent validity.

Results: Participants were mostly female (79%) and white (86%) with a mean (SD) age of 56 (13) and RA duration of 12 (9) yr; 10% were diagnosed ≤ 2 yr. In general, PROMIS fatigue measures correlated highly with VAS of fatigue, pain and patient global, moderately with mHAQ, morning stiffness, CDAI and MD global and weakly with joint counts (see Table). A dose response relationship across CDAI levels was evident in all measures.

Conclusion: Our study contributes preliminary evidence of the feasibility of the 3 PROMIS fatigue instruments as part of routine RA visits and of construct validity with legacy measures and clinical indicators. All PROMIS fatigue measures correlated highly with the fatigue VAS; while the Fatigue CAT was most strongly associated with legacy measures and offers greater precision, the 7-item short form and single Fatigue item also performed adequately and are useful when paper-based or briefer versions are needed. PROMIS scores can be compared against population norms. Further evaluation of responsiveness and validity across diverse groups of patients and settings is warranted.

 

Fatigue VAS

PROMIS CAT

PROMIS Short Form

Fatigue Item*

Mean (SEM)

39.9 (2.8)

54.3 (0.9)

53.6 (0.8)

2.6 (0.1)

Median (IQR)

35.0 [61]

53.5 [15]

53.7 [13]

3 [1]

Range

0 – 97

26.3 – 76.0

29.4 – 71.1

1-5

Floor/Ceiling

11% / 1%

2% / 1%

1% / 0%

12% / 3.2%

Correlations†

 

 

 

 

   Fatigue VAS

—

.856

.787

.812

   Pain VAS

.749

.677

.596

.591

   Patient Global

.779

.707

.661

.604

   MHAQ

.496

.497

.563

.497

   AM Stiff (min)

.430

.320

.323

.339

   CDAI

.641

.620

.558

.557

   MD Global

.436

.408

.398

.383

   Swollen Joint (28)

.220

.247

.146 (NS)

.195

   Tender Joints (28)

.337

.398

.366

.372

Health Rating

-.586

-.541

-.636

-.547

CDAI (Mean SD)

 

 

 

 

   Remission

12.7 (17.2)a

46.1 (8.5)a

47.4 (7.5)a

1.9 (0.7)a

   Low

45.3 (29.0)b

55.6 (8.8)b

54.8 (9.2)b

2.7 (0.9)b

   Moderate

57.5 (27.9)c**

59.5 (6.9)c*

58.0 (5.0)b,c

3.0 (0.7)b,c

   High

64.3 (21.4)c

62.3 (9.4)c

58.8 (7.3)c

3.4 (0.9)c

*From Global Health SF.  †Different superscripts reflect significantly different values (p<.05); **p<.06.

 


Disclosure:

S. J. Bartlett,
None;

A. M. Orbai,
None;

T. Duncan,
None;

C. O. Bingham III,

PCORI,

2,

OMERACT officer,

6.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/how-well-do-the-three-generic-patient-reported-outcomes-measurement-information-system-fatigue-instruments-perform-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology